BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24122303)

  • 1. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
    Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
    Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
    Kohn CG; Parker MW; Limone BL; Coleman CI
    Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
    Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
    BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine: a review of its use in chronic stable angina pectoris.
    Keating GM
    Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
    Bălan H
    Rom J Intern Med; 2010; 48(4):361-9. PubMed ID: 21528766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of ranolazine in chronic stable angina patients.
    Patel PD; Arora RR
    Vasc Health Risk Manag; 2008; 4(4):819-24. PubMed ID: 19065998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on ranolazine in the management of angina.
    Codolosa JN; Acharjee S; Figueredo VM
    Vasc Health Risk Manag; 2014; 10():353-62. PubMed ID: 25028555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine for the management of coronary artery disease.
    Cheng JW
    Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
    Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
    Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on ranolazine in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
    Ling H; Packard KA; Burns TL; Hilleman DE
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
    Ayyasamy L; Bagepally BS
    Clin Ther; 2023 May; 45(5):458-465. PubMed ID: 37087299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ranolazine--new treatment of chronic stable angina pectoris].
    Ahlehoff O; Hansen PR
    Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.